Mogroside IV

Drug Profile

Mogroside IV

Alternative Names: CB-5300; Mogroside-IV; Mogrovir

Latest Information Update: 23 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Canopus BioPharma
  • Class Antivirals; Triterpenoid sapogenins
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Hepatitis C
  • Preclinical Dengue

Most Recent Events

  • 23 Sep 2015 No recent reports on development identified - Phase-II for Hepatitis C in USA (PO)
  • 01 Jul 2014 Clinical trials in Hepatitis C (Combination therapy, Treatment-naive, in genotype-1 patients) in China before July 2014 (PO)
  • 01 Jul 2014 Final efficacy and adverse events data from a compassionate clinical trial in Hepatitis C released by Canopus BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top